2020
Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry)
Saad M, Tobolski J, Kolte D, Wang Y, Minges K, Hira RS, Curtis JP, Abbott JD. Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). The American Journal Of Cardiology 2020, 133: 182-184. PMID: 32819682, DOI: 10.1016/j.amjcard.2020.07.029.Peer-Reviewed Original Research
2019
DURATION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS ON ORAL ANTICOAGULANTS IN CLINICAL PRACTICE
Tobolski J, Abbott J, Kolte D, Curtis J, Hira R, Wang Y, Minges K. DURATION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS ON ORAL ANTICOAGULANTS IN CLINICAL PRACTICE. Journal Of The American College Of Cardiology 2019, 73: 1081. DOI: 10.1016/s0735-1097(19)31688-2.Peer-Reviewed Original Research
2015
Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study)
Gupta A, Chui P, Zhou S, Spertus JA, Geda M, Lorenze N, Lee I, Onofrio G, Lichtman JH, Alexander KP, Krumholz HM, Curtis JP. Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). The American Journal Of Cardiology 2015, 116: 1-7. PMID: 25937348, PMCID: PMC4466069, DOI: 10.1016/j.amjcard.2015.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsBody Mass IndexCohort StudiesFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPrevalenceRecombinant ProteinsRisk AssessmentRisk FactorsSex DistributionTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsExcess dosingAcute myocardial infarctionCoronary interventionMultivariable analysisMyocardial infarctionUnderwent Percutaneous Coronary InterventionLower body weightOlder patientsYounger patientsUnfractionated heparinMedical recordsUnivariate analysisAnticoagulant agentsAnticoagulant drugsBody weightPatientsDosingYounger ageLogistic regressionYoung womenAnticoagulantsGender-based differences